Target Volume Definition in Primary Prostate Cancer Radiotherapy

  • Dirk Böhmer
Part of the Medical Radiology book series (MEDRAD)


The organ contouring section of this book provides a summary of the available evidence on prostate cancer target volume definition. The reader will find comprehensive data supporting the extension of the clinical target volume beyond the prostate for patients with risk factors such as a high pre-treatment PSA value or a high Gleason score. Furthermore the necessity to adapt planning target volume margins according to the applied treatment technique and verification method is elaborated.


Seminal Vesicle Planning Target Volume National Comprehensive Cancer Network Clinical Target Volume Seminal Vesicle Invasion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Al-Mamgani A, van Putten WL, van der Wielen GJ, Levendag PC, Incrocci L (2011) Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96–10 trial). Int J Radiat Oncol Biol Phys 79(4):1004–1012. doi: 10.1016/j.ijrobp.2009.12.039 PubMedCrossRefGoogle Scholar
  2. Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari MG, Pinnaro P, Pinzi V, Arcangeli G (2012) Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84(5):1172–1178. doi: 10.1016/j.ijrobp.2012.02.049 PubMedCrossRefGoogle Scholar
  3. Beckendorf V, Guerif S, Le Prise E, Cosset JM, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud JM, Maingon P, Hannoun-Levi JM, Malissard L, Simon JM, Pommier P, Hay M, Dubray B, Lagrange JL, Luporsi E, Bey P (2011) 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 80(4):1056–1063. doi: 10.1016/j.ijrobp.2010.03.049 PubMedCrossRefGoogle Scholar
  4. Boehmer D, Maingon P, Poortmans P, Baron MH, Miralbell R, Remouchamps V, Scrase C, Bossi A, Bolla M (2006) Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol: J Eur Soc Ther Radiol Oncol 79(3):259–269. doi: 10.1016/j.radonc.2006.05.012 CrossRefGoogle Scholar
  5. D’Amico AV, Whittington R, Kaplan I, Beard C, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A, Coleman CN (1997b) Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV. Int J Radiat Oncol Biol Phys 39(2):335–340PubMedCrossRefGoogle Scholar
  6. D’Amico AV, Whittington R, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A (1997a) Outcome based staging for clinically localized adenocarcinoma of the prostate. J urol 158(4):1422–1426PubMedCrossRefGoogle Scholar
  7. D’Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Coleman CN (1999) Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol: Off J Am Soc Clin Oncol 17(1):168–172Google Scholar
  8. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA J Am Med Assoc 280(11):969–974CrossRefGoogle Scholar
  9. Davis BJ, Pisansky TM, Wilson TM, Rothenberg HJ, Pacelli A, Hillman DW, Sargent DJ, Bostwick DG (1999) The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer 85(12):2630–2637PubMedCrossRefGoogle Scholar
  10. de Crevoisier R, Tucker SL, Dong L, Mohan R, Cheung R, Cox JD, Kuban DA (2005) Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 62(4):965–973. doi: 10.1016/j.ijrobp.2004.11.032 PubMedCrossRefGoogle Scholar
  11. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, Moore AR, Morgan RC, Russell JM, Scrase CD, Stephens RJ, Syndikus I, Parmar MK (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8(6):475–487. doi: 10.1016/S1470-2045(07)70143-2 PubMedCrossRefGoogle Scholar
  12. Epstein JI, Carmichael MJ, Pizov G, Walsh PC (1993) Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J urol 150(1):135–141PubMedGoogle Scholar
  13. Graf R, Wust P, Budach V, Boehmer D (2009) Potentials of on-line repositioning based on implanted fiducial markers and electronic portal imaging in prostate cancer radiotherapy. Radiat Oncol 4:13. doi: 10.1186/1748-717X-4-13 PubMedCentralPubMedCrossRefGoogle Scholar
  14. Graf R, Boehmer D, Nadobny J, Budach V, Wust P (2012) Appropriate patient instructions can reduce prostate motion. Radiat Oncol 7:125. doi: 10.1186/1748-717X-7-125 PubMedCentralPubMedCrossRefGoogle Scholar
  15. Heemsbergen WD, Hoogeman MS, Witte MG, Peeters ST, Incrocci L, Lebesque JV (2007) Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 GY versus 78 Gy. Int J Radiat Oncol Biol Phys 67(5):1418–1424. doi: 10.1016/j.ijrobp.2006.11.014 PubMedCrossRefGoogle Scholar
  16. International Commission on Radiation Units and Measurements (1993) Prescribing, recording, and reporting photon beam therapy. ICRU report 50, Oxford University PressGoogle Scholar
  17. International Commission on Radiation Units and Measurements (1999) Prescribing, recording, and reporting photon beam therapy (Supplement to ICRU report 50). ICRU Report 62, Oxford University PressGoogle Scholar
  18. International Commission on Radiation Units and Measurements (2010) Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). ICRU report 83, Oxford University Press vol 10(1). doi: 10.1093/jicru/ndq002
  19. Kapanen M, Collan J, Beule A, Seppala T, Saarilahti K, Tenhunen M (2012) Commissioning of MRI-only based treatment planning procedure for external beam radiotherapy of prostate. Magn Reson Med: Off j Soc Magn Reson Med/Soc Mag Reson Med. doi: 10.1002/mrm.24459 Google Scholar
  20. Kotte AN, Hofman P, Lagendijk JJ, van Vulpen M, van der Heide UA (2007) Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys 69(2):419–425. doi: 10.1016/j.ijrobp.2007.03.029 PubMedCrossRefGoogle Scholar
  21. Kestin L, Goldstein N, Vicini F, Yan D, Korman H, Martinez A (2002) Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys 54(3):686–697PubMedCrossRefGoogle Scholar
  22. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67–74. doi: 10.1016/j.ijrobp.2007.06.054 PubMedCrossRefGoogle Scholar
  23. Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H, Brundage M, Kwan W (2005) Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol: Off J Am Soc Clin Oncol 23(25):6132–6138. doi: 10.1200/JCO.2005.06.153 CrossRefGoogle Scholar
  24. Norkus D, Miller A, Kurtinaitis J, Haverkamp U, Popov S, Prott FJ, Valuckas KP (2009) A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity. Strahlenther Onkol 185(11):715–721. doi: 10.1007/s00066-009-1982-z PubMedCrossRefGoogle Scholar
  25. Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Konski AA, Movsas B, Greenberg RE, Uzzo RG, Ma CM, McNeeley SW, Buyyounouski MK, Price RA Jr (2006) Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64(2):518–526. doi: 10.1016/j.ijrobp.2005.07.970 PubMedCentralPubMedCrossRefGoogle Scholar
  26. Rasch C, Barillot I, Remeijer P, Touw A, van Herk M, Lebesque JV (1999) Definition of the prostate in CT and MRI: a multi-observer study. Int J Radiat Oncol Biol Phys 43(1):57–66PubMedCrossRefGoogle Scholar
  27. Schwartz DJ, Sengupta S, Hillman DW, Sargent DJ, Cheville JC, Wilson TM, Mynderse LA, Choo R, Davis BJ (2007) Prediction of radial distance of extraprostatic extension from pretherapy factors. Int J Radiat Oncol Biol Phys 69(2):411–418. doi: 10.1016/j.ijrobp.2007.03.016 PubMedCrossRefGoogle Scholar
  28. Smeenk RJ, Teh BS, Butler EB, van Lin EN, Kaanders JH (2010) Is there a role for endorectal balloons in prostate radiotherapy? A systematic review. Radiother Oncol: J Eur Soc Ther Radiol Oncol 95(3):277–282. doi: 10.1016/j.radonc.2010.04.016 CrossRefGoogle Scholar
  29. Sohayda C, Kupelian PA, Levin HS, Klein EA (2000) Extent of extracapsular extension in localized prostate cancer. Urology 55(3):382–386PubMedCrossRefGoogle Scholar
  30. Teh BS, Bastasch MD, Wheeler TM, Mai WY, Frolov A, Uhl BM, Lu HH, Carpenter LS, Chiu JK, McGary J, Woo SY, Grant WH 3rd, Butler EB (2003) IMRT for prostate cancer: defining target volume based on correlated pathologic volume of disease. Int J Radiat Oncol Biol Phys 56(1):184–191PubMedCrossRefGoogle Scholar
  31. van Herk M (2004) Errors and margins in radiotherapy. Semin Radiat Oncol 14(1):52–64. doi: 10.1053/j.semradonc.2003.10.003 PubMedCrossRefGoogle Scholar
  32. van Veggel BA, van Oort IM, Witjes JA, Kiemeney LA, Hulsbergen-van de Kaa CA (2011) Quantification of extraprostatic extension in prostate cancer: different parameters correlated to biochemical recurrence after radical prostatectomy. Histopathology 59(4):692–702. doi: 10.1111/j.1365-2559.2011.03986.x PubMedCrossRefGoogle Scholar
  33. Wheeler TM, Dillioglugil O, Kattan MW, Arakawa A, Soh S, Suyama K, Ohori M, Scardino PT (1998) Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1–2 prostate cancer. Hum Pathol 29(8):856–862PubMedCrossRefGoogle Scholar
  34. Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J (2011) Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 81(5):1271–1278. doi: 10.1016/j.ijrobp.2010.07.1984 PubMedCrossRefGoogle Scholar
  35. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, Shipley WU (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA J Am Med Assoc 294(10):1233–1239. doi: 10.1001/jama.294.10.1233 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Radiation OncologyCharité University MedicineBerlinGermany

Personalised recommendations